Cargando…
Genome sequencing of SARS-CoV-2 reveals the prevalence of variant B 1.1.7 in Egypt
Recently, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) resulted in Coronavirus Disease 2019 (COVID-19) outbreak. A new SARS-CoV-2 strain is expected to emerge in late 2020, including B.1.1.7. The high transmission rate of SARS-CoV-2 B.1.1.7 has raised public health concerns in se...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677423/ https://www.ncbi.nlm.nih.gov/pubmed/34923158 http://dx.doi.org/10.1016/j.meegid.2021.105191 |
_version_ | 1784616145284759552 |
---|---|
author | Seadawy, Mohamed G. Gad, Ahmed F. Abo-Elmaaty, Sabah A. Hassan, Mervat G. |
author_facet | Seadawy, Mohamed G. Gad, Ahmed F. Abo-Elmaaty, Sabah A. Hassan, Mervat G. |
author_sort | Seadawy, Mohamed G. |
collection | PubMed |
description | Recently, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) resulted in Coronavirus Disease 2019 (COVID-19) outbreak. A new SARS-CoV-2 strain is expected to emerge in late 2020, including B.1.1.7. The high transmission rate of SARS-CoV-2 B.1.1.7 has raised public health concerns in several countries. Hence, in this study, we assessed the sequencing of SARS-COV2 to reveals the prevalence of the SARS-CoV-2 Alpha variant (B 1.1.7) in Egypt. We found that the viral transmission of the alpha variant is expanding. Moreover, based on hospitalizations and case fatality rates, there is a potential for increasing severity. There was no effect on susceptibility to Emergency Use Authorization monoclonal antibody treatments. However, there was minimal impact on neutralization by convalescent and post-vaccination sera. Samples have been clustered into the 20D sub clade for the majority of them. The eight samples shown in our study are considered the first recorded samples with the Alpha variant in Egypt. Therefore, The Egyptian government, represented by the Ministry of Health, must take all measures to examine the compatibility of the currently used vaccines with this new strain and the feasibility of the treatment protocol presently used with such strains developed in the Arab Republic of Egypt. |
format | Online Article Text |
id | pubmed-8677423 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Authors. Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86774232021-12-17 Genome sequencing of SARS-CoV-2 reveals the prevalence of variant B 1.1.7 in Egypt Seadawy, Mohamed G. Gad, Ahmed F. Abo-Elmaaty, Sabah A. Hassan, Mervat G. Infect Genet Evol Article Recently, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) resulted in Coronavirus Disease 2019 (COVID-19) outbreak. A new SARS-CoV-2 strain is expected to emerge in late 2020, including B.1.1.7. The high transmission rate of SARS-CoV-2 B.1.1.7 has raised public health concerns in several countries. Hence, in this study, we assessed the sequencing of SARS-COV2 to reveals the prevalence of the SARS-CoV-2 Alpha variant (B 1.1.7) in Egypt. We found that the viral transmission of the alpha variant is expanding. Moreover, based on hospitalizations and case fatality rates, there is a potential for increasing severity. There was no effect on susceptibility to Emergency Use Authorization monoclonal antibody treatments. However, there was minimal impact on neutralization by convalescent and post-vaccination sera. Samples have been clustered into the 20D sub clade for the majority of them. The eight samples shown in our study are considered the first recorded samples with the Alpha variant in Egypt. Therefore, The Egyptian government, represented by the Ministry of Health, must take all measures to examine the compatibility of the currently used vaccines with this new strain and the feasibility of the treatment protocol presently used with such strains developed in the Arab Republic of Egypt. The Authors. Published by Elsevier B.V. 2022-01 2021-12-17 /pmc/articles/PMC8677423/ /pubmed/34923158 http://dx.doi.org/10.1016/j.meegid.2021.105191 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Seadawy, Mohamed G. Gad, Ahmed F. Abo-Elmaaty, Sabah A. Hassan, Mervat G. Genome sequencing of SARS-CoV-2 reveals the prevalence of variant B 1.1.7 in Egypt |
title | Genome sequencing of SARS-CoV-2 reveals the prevalence of variant B 1.1.7 in Egypt |
title_full | Genome sequencing of SARS-CoV-2 reveals the prevalence of variant B 1.1.7 in Egypt |
title_fullStr | Genome sequencing of SARS-CoV-2 reveals the prevalence of variant B 1.1.7 in Egypt |
title_full_unstemmed | Genome sequencing of SARS-CoV-2 reveals the prevalence of variant B 1.1.7 in Egypt |
title_short | Genome sequencing of SARS-CoV-2 reveals the prevalence of variant B 1.1.7 in Egypt |
title_sort | genome sequencing of sars-cov-2 reveals the prevalence of variant b 1.1.7 in egypt |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677423/ https://www.ncbi.nlm.nih.gov/pubmed/34923158 http://dx.doi.org/10.1016/j.meegid.2021.105191 |
work_keys_str_mv | AT seadawymohamedg genomesequencingofsarscov2revealstheprevalenceofvariantb117inegypt AT gadahmedf genomesequencingofsarscov2revealstheprevalenceofvariantb117inegypt AT aboelmaatysabaha genomesequencingofsarscov2revealstheprevalenceofvariantb117inegypt AT hassanmervatg genomesequencingofsarscov2revealstheprevalenceofvariantb117inegypt |